Yuan‐Ching Chang

机构：Mackay Memorial Hospital, Taipei Tzu Chi Hospital · ORCID：0000-0001-7625-606X

发表论文 100 篇 · 总被引 2605 次 · h-index 23

代表论文

• Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01 (2024 · Journal of Clinical Oncology · 被引 163)
• Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer (2024 · Journal of Clinical Oncology · 被引 85)
• Neoadjuvant–adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial (2024 · Nature Communications · 被引 32)
• Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer (2023 · JAMA Oncology · 被引 28)
• Unraveling the connections between gut microbiota, stress, and quality of life for holistic care in newly diagnosed breast cancer patients (2023 · Scientific Reports · 被引 15)
• Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician’s choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial. (2023 · Journal of Clinical Oncology · 被引 10)